Angeliki Cooney

Angeliki Cooney has established herself as a prominent figure in the life sciences industry over the past twenty years, working from her base in Wynantskill, NY. Her expertise is facilitating the development and market launch of therapies for chronic diseases, rare conditions, and cancer, focusing on ensuring patient access to these innovations.

Angeliki's career is distinguished by her role in advising biopharmaceutical companies on strategies for omnichannel customer engagement, digital transformation, and commercial operations. Her innovative contributions include developing several key software-as-a-service (SaaS) products for the industry, for which she has secured three patents.

Recently, she took on the Senior Vice President of Life Sciences role at Avenga, where she directed the firm's expansion strategies in the U.S. market. Avenga, a global tech consultancy, serves significant pharmaceutical and biotech companies. Under Angeliki's leadership, the firm developed a considerable client base, enhancing its presence and operations in the competitive U.S. market.

Before her tenure at Avenga, she worked at Axtria as the Principal Group Lead of Commercial Excellence. There, she managed a diverse portfolio of biotech and pharmaceutical clients across the U.S. and Europe, significantly growing the company's reach and revenue by pioneering new commercial strategies and client engagement models.

Her earlier roles include serving as the Senior Director of Life Sciences Consulting at Gartner, where she was pivotal in bridging the operational and strategic divides between life sciences enterprises and their I.T. departments. Her career also spans significant positions at New York Life Insurance, IMS Health, and Z.S. Associates, where she led initiatives that significantly enhanced digital and analytical capabilities.

Angeliki Cooney's path to the pharmaceutical industry was influenced early on by a childhood internship at her godfather's pharmacy in Europe, which sparked a deep interest in medical therapies and their applications. She pursued higher education with vigor, earning an MBA from Harvard Business School and an M.S. in Chemical Engineering from the University of Patra, Greece.